Observational Study of THC Concentrations in Acute Cannabinoid Intoxication

Launched by ANEBULO PHARMACEUTICALS · Aug 24, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how much tetrahydrocannabinol (THC), the active ingredient in cannabis, is in the blood of people who come to the emergency department after using cannabis. THC can affect people in different ways, leading to symptoms like anxiety, impaired judgment, or changes in perception. By studying the levels of THC and its breakdown products in the blood, researchers hope to better understand the effects of cannabis intoxication and how it impacts patients.

To participate in this study, you must have recently used cannabis (within the last 12 hours) and be experiencing significant symptoms related to its use when you arrive at the emergency room. Participants should be able to communicate and give consent, whether they are adults or have a parent or legal representative with them if they are under 18. It's important to note that individuals with certain conditions, like cannabis withdrawal or who were brought in by law enforcement, cannot take part in this study. If you join, you'll help researchers gather valuable information that could improve care for future patients experiencing similar issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• 1. Subject visits emergency department for acute cannabinoid intoxication as evidenced by the following criteria:
• • 1. Recent cannabis use within the last 12 hours
• • 2. Clinically significant physiological abnormalities associated with cannabis use or problematic behavioral or psychological changes (e.g., altered perception, impaired motor coordination, euphoria, anxiety, a sensation of slowed time, impaired judgment, social withdrawal) that developed during, or shortly after, cannabis use
• • 2. Subject (and/or parent/LAR when required) has the ability to communicate with comprehension with the study personnel at the time of consent/assent and the gathering of data other than plasma samples.
• • 3. Subject (and/or parent/LAR when required) is willing and able to provide informed consent/assent.
• • Exclusion criteria
• A potential subject who meets any of the following criteria will be excluded from participation in this study:
• • 1. Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.
• • 2. Individuals under the age of 18 who do not have a parent or legal representative present during the time at the ED.
• • 3. Patients presenting with signs or symptoms attributable to another medical condition or better explained by another mental disorder.
• • 4. Patient presenting with cannabis hyperemesis syndrome (CHS) or cannabis withdrawal syndrome (CWS)
• • 5. Patients who are brought in by law enforcement, i.e., cannabis intoxication associated with a vehicle accident (driving under the influence).